NervGen Pharma Corp. (NGEN)
NASDAQ: NGEN · Real-Time Price · USD
4.150
+0.130 (3.23%)
At close: Mar 9, 2026, 4:00 PM EDT
4.150
0.00 (0.00%)
After-hours: Mar 9, 2026, 4:00 PM EDT
NervGen Pharma Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Selling, General & Admin | 10.43 | 9.21 | 9.73 | 6.41 | 5.94 | 5.03 | |
| Research & Development | 14.81 | 15.73 | 8.05 | 16.61 | 6.87 | 6.16 | |
| Operating Expenses | 25.24 | 24.93 | 17.78 | 23.03 | 12.81 | 11.2 | |
| Operating Income | -25.24 | -24.93 | -17.78 | -23.03 | -12.81 | -11.2 | |
| Interest Expense | - | - | - | -0.51 | - | - | |
| Interest & Investment Income | 0.44 | 0.81 | 0.55 | 0.2 | 0.03 | 0.02 | |
| Currency Exchange Gain (Loss) | 0.04 | 0.25 | -0.16 | 0.71 | 0.06 | -0.01 | |
| Other Non Operating Income (Expenses) | -0.82 | -0.14 | -4.99 | 1.91 | - | - | |
| Pretax Income | -25.57 | -24.01 | -22.38 | -20.72 | -12.73 | -11.19 | |
| Net Income | -25.57 | -24.01 | -22.38 | -20.72 | -12.73 | -11.19 | |
| Net Income to Common | -25.57 | -24.01 | -22.38 | -20.72 | -12.73 | -11.19 | |
| Shares Outstanding (Basic) | 71 | 67 | 59 | 53 | 39 | 32 | |
| Shares Outstanding (Diluted) | 71 | 67 | 59 | 53 | 39 | 32 | |
| Shares Change (YoY) | 10.41% | 13.55% | 12.61% | 34.00% | 22.35% | 23.97% | |
| EPS (Basic) | -0.36 | -0.36 | -0.38 | -0.39 | -0.32 | -0.35 | |
| EPS (Diluted) | -0.36 | -0.36 | -0.38 | -0.39 | -0.32 | -0.35 | |
| Free Cash Flow | -16.76 | -16.84 | -11.3 | -17.81 | -8.27 | -6.3 | |
| Free Cash Flow Per Share | -0.23 | -0.25 | -0.19 | -0.34 | -0.21 | -0.20 | |
| EBITDA | -25.2 | -24.87 | -17.72 | -22.91 | -12.77 | -11.16 | |
| D&A For EBITDA | 0.04 | 0.06 | 0.06 | 0.12 | 0.04 | 0.04 | |
| EBIT | -25.24 | -24.93 | -17.78 | -23.03 | -12.81 | -11.2 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.